CommercialCoverageHigh impact
06.02.36d, Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)
Independence Blue Cross·Gastroenterology, General Surgery, Oncology·Medical Policy
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Independence Administrators has reissued policy 06.02.36d regarding molecular testing for management of pancreatic cysts and Barrett's esophagus. This is a policy reissue effective 06/24/2026; however, the specific coverage changes, billing code requirements, and prior authorization rules are not detailed in the provided policy header. The billing team must obtain the full policy text to identify affected CPT/HCPCS codes, coverage criteria, and any new prior authorization mandates.
Action Required
By 06/24/2026: Billing team must obtain and review the complete policy text from https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-06-02-36d. Identify all specific CPT/HCPCS codes affected, coverage criteria, and prior authorization requirements. Update billing system rules, encounter forms, and provider documentation templates accordingly. Brief providers and billing staff on changes. Verify compliance before the effective date to prevent claim denials for pancreatic cyst and Barrett's esophagus molecular testing cases.